Accelerated bone mass senescence after hematopoietic stem cell transplantation

Area of Science:

• Hematology
• Orthopedics
• Transplantation Medicine

Background:

• Osteoporosis and avascular necrosis (AVN) are significant long-term complications following hematopoietic stem cell transplantation (HSCT).
• These conditions can lead to prolonged disability and impact patient quality of life post-transplant.

Purpose of the Study:

• To evaluate the extent of bone loss, AVN incidence, and osteogenic cell compartment changes in long-term survivors after autologous (auto) and allogeneic (allo) HSCT.
• To outline current management strategies for these post-transplant bone complications.

Main Methods:

• Retrospective analysis of bone damage in 100 long-term HSCT survivors (50 auto-HSCT, 50 allo-HSCT) up to 15 years post-transplant.
• Assessment of bone mineral density (BMD) at various skeletal sites and evaluation of AVN incidence.
• Correlation of bone complications with factors such as steroid treatment and chronic graft-versus-host disease.

Main Results:

• Both auto- and allo-HSCT recipients experienced accelerated bone mineral loss and micro-architectural deterioration early post-transplant.
• Phalangeal BMD remained low long-term, indicating persistent bone alterations, while lumbar spine BMD showed potential for improvement.
• Allogeneic HSCT recipients had a higher incidence of AVN; longer steroid treatment duration and chronic graft-versus-host disease were associated with increased bone loss and AVN risk.

Conclusions:

• Patients undergoing HSCT are at high risk for significant bone loss and AVN, with persistent effects on bone micro-architecture.
• Reduced osteogenic cell regeneration capacity contributes to lower BMD and higher AVN rates.
• Regular bone status evaluation and prompt initiation of anti-resorptive therapy are recommended for all HSCT recipients.